Century Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell IPSC and other ETFs, options, and stocks.

About IPSC

Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. It focuses on harnessing the power of adult stem cells to develop curative allogeneic cell therapies for cancer. 

CEO
Brent Pfeiffenberger
CEOBrent Pfeiffenberger
Employees
150
Employees150
Headquarters
Philadelphia, Pennsylvania
HeadquartersPhiladelphia, Pennsylvania
Founded
2018
Founded2018
Employees
150
Employees150

IPSC Key Statistics

Market cap
200.92M
Market cap200.92M
Price-Earnings ratio
-7.40
Price-Earnings ratio-7.40
Dividend yield
Dividend yield
Average volume
4.10M
Average volume4.10M
High today
$2.32
High today$2.32
Low today
$1.96
Low today$1.96
Open price
$2.00
Open price$2.00
Volume
2.61M
Volume2.61M
52 Week high
$2.32
52 Week high$2.32
52 Week low
$0.3418
52 Week low$0.3418

Stock Snapshot

Century Therapeutics(IPSC) stock is priced at $2.31, giving the company a market capitalization of 200.92M. It carries a P/E multiple of -7.40.

On 2026-01-15, Century Therapeutics(IPSC) stock traded between a low of $1.96 and a high of $2.32. Shares are currently priced at $2.31, which is +17.9% above the low and -0.4% below the high.

Century Therapeutics(IPSC) shares are trading with a volume of 2.61M, against a daily average of 4.1M.

During the past year, Century Therapeutics(IPSC) stock moved between $0.34 at its lowest and $2.32 at its peak.

During the past year, Century Therapeutics(IPSC) stock moved between $0.34 at its lowest and $2.32 at its peak.

People also own

Based on the portfolios of people who own IPSC. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the .